Insmed

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Insmed reports robust earnings, eyes pipeline expansion and regulatory support

Insmed's strong financial performance in 2022, driven by ARIKAYCE revenue and prudent cost management, sets a solid foundation for future growth. The company's focus on pipeline expansion, regulatory enthusiasm for brensocatib, and strategic milestones position it well for success. Challenges in the NTM market and pandemic-related impacts require careful navigation, but opportunities in new trials and gene therapy offer promising avenues for growth.

Insmed excels in Q1 with revenue growth and trial milestones

Insmed's strong Q1 performance driven by revenue growth and successful trial enrollments.
Challenges include regulatory differences and unblinding requirements for trial outcomes.
Opportunities lie in expanding ARIKAYCE's market reach and showcasing research efforts.
Financial stability and positive program reviews position Insmed well for future growth.

Insmed achieves record sales, strengthens capabilities in untreatable diseases

Insmed's Q2 2023 performance reflects robust sales growth, improved financial stability, and strategic acquisitions, positioning the company for future success.
The company's strengths lie in its commercial performance, innovative treatment formulations, and enhanced capabilities in synthetic rescue for untreatable diseases.
While facing challenges in clinical trial success and financial management, Insmed has opportunities to leverage its R&D portfolio, expedite drug approvals, and drive growth in key therapeutic areas.

Insmed reports record revenues and advances in trials, poised for growth

Insmed's Q3 2023 performance reflects record revenues for ARIKAYCE and positive trial results for brensocatib, positioning the company for continued growth.
Strong cash reserves, successful commercial activities, and promising trial data highlight Insmed's strengths and potential for future success in the biopharmaceutical market.
While facing funding challenges and trial complexities, Insmed has opportunities to leverage trial outcomes, enhance treatment efficacy, and secure financing for growth.
Overall, Insmed's strategic focus on product performance, financial stability, and innovation underscores its commitment to advancing therapies and driving shareholder value.

Insmed reports strong earnings, projects brensocatib sales exceeding $5B

Insmed's Q4 2023 earnings call highlighted strong financial performance, positive trial results, and strategic initiatives to maintain cash balance and drive commercial opportunities
The company's focus on patient-centric approaches, diverse early-stage assets, and opportunities for label expansion and commercial success position Insmed for future growth
While facing challenges related to placebo effects, regulatory requirements, and therapeutic advancements, Insmed's emphasis on reducing exacerbation rates and pursuing innovative therapies presents avenues for overcoming obstacles
With a robust cash position, promising pipeline developments, and a clear commercial outlook, Insmed demonstrates resilience and potential for market impact in the biopharmaceutical industry

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BRIDGEWATER, N.J., May 13, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) announced today the closing of the previously announced registered underwritten public offering (the "Equity Offering") of 11,500,000 shares of its common stock (the "Shares"), including 1,500,000 Shares issued pursuant to the exercise in full of the underwriters' option to purchase additional Shares, at a price to the public of $25.00 per share before deducting underwriting discounts and commissions, and the previously announced registered underwritten public offering (the "Notes Offering") of $575 million aggregate principal amount of its 0.75% convertible senior notes due 2028 (the "Notes"), including $75 million aggregate principal amount of Notes purchased pursuant to the exercise in full of the underwriters' option to purchase additional Notes, solely to cover over-allotments.

Insmed Announces Closing of Public Offerings of Common Stock and Convertible Senior Notes and Full Exercise of Underwriters' Options to Purchase Additional Shares and Notes

BRIDGEWATER, N.J., May 11, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) announced today that it priced a registered underwritten public offering of 10,000,000 shares of its common stock (the "Shares") at a price to the public of $25.00 per share before deducting underwriting discounts and commissions, and a registered underwritten public offering of $500 million aggregate principal amount of its 0.75% convertible senior notes due 2028 (the "Notes").

Insmed Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028

The stock price of Insmed Incorporated (NASDAQ: INSM) decreased by over 15% during intraday trading this morning. This is why it happened.

INSM Stock: Over 15% Decrease Intraday Explanation

BRIDGEWATER, N.J., May 10, 2021 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM) announced today that it intends to offer and sell $250 million of its common stock (the "Shares") and $500 million aggregate principal amount of its convertible senior notes due 2028 (the "Notes") in separate concurrent underwritten public offerings, a portion of which will be used to repurchase Insmed's existing outstanding convertible senior notes due 2025.

Insmed Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028

Insmed Incorporated (INSM) CEO Will Lewis on Q1 2021 Results - Earnings Call Transcript

BRIDGEWATER, N.J., May 6, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the first quarter ended March 31, 2021 and provided a business update.

Insmed Reports First Quarter 2021 Financial Results and Provides Business Update

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline

BRIDGEWATER, N.J., April 22, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2021 financial results on Thursday, May 6, 2021.

Insmed to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021

BRIDGEWATER, N.J., March 23, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved ARIKAYCE® (amikacin liposome inhalation suspension) for the treatment of patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) who did not sufficiently respond to prior treatment with a multidrug regimen (MDR).

ARIKAYCE® (amikacin liposome inhalation suspension) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to Prior Treatment with MDR

Insmed Incorporated (INSM) CEO Will Lewis on Q4 2020 Results - Earnings Call Transcript

BRIDGEWATER, N.J., Feb. 25, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31,...

Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Insmed Incorporated (NASDAQ: INSM) has announced topline results from the Phase 1 study evaluating treprostinil palmitil inhalation powder (TPIP) in healthy volunteers. The company plans to present complete data from this study at an upcoming medical meeting.

Insmed's Inhaled Treprostinil Palmitil Is Safe; Healthy Volunteers Study Show

BRIDGEWATER, N.J., Feb. 19, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced topline results from the Phase 1 study of treprostinil palmitil inhalation...

Insmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP)

BRIDGEWATER, N.J., Feb. 16, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release topline data from its Phase 1 healthy volunteer...

Insmed to Host Conference Call to Discuss Topline Data from Treprostinil Palmitil Inhalation Powder Phase 1 Study

BRIDGEWATER, N.J., Feb. 12, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth quarter and full year 2020 financial...

Insmed to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021

Insmed (INSM) doses the first patient in the phase III ASPEN study evaluating its pipeline candidate brensocatib for the treatment of patients with bronchiectasis.

Insmed (INSM) Starts Dosing in Phase III Bronchiectasis Study

Aurinia Pharmaceuticals

Cytokinetics

NeoGenomics

Turning Point Therapeutics

In this article we present the list of Top 10 Healthcare Stocks for the Future. Click to skip ahead and see the  Top 5 Healthcare Stocks for the Future .

Top 10 Healthcare Stocks for the Future

BRIDGEWATER, N.J., Nov. 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the virtual Evercore ISI 3rd Annual...

Insmed to Present at the Evercore ISI 3rd Annual HealthCONx Conference

BRIDGEWATER, N.J., Nov. 13, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the European Medicines Agency (EMA) has granted Priority Medicines...

Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)

Insmed Incorporated (INSM) CEO Will Lewis on Q3 2020 Results - Earnings Call Transcript

BRIDGEWATER, N.J., Oct. 29, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the third quarter ended September 30, 2020, and...

Insmed Reports Third Quarter 2020 Financial Results and Provides Business Update

BRIDGEWATER, N.J., Oct. 28, 2020 /PRNewswire/ — Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the European Commission (EC) has granted marketing authorization for...

European Commission Grants Marketing Authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Treatment Options

BRIDGEWATER, N.J., Oct. 20, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2020 financial results on...

Insmed to Host Third Quarter 2020 Financial Results Conference Call on Thursday, October 29, 2020

Alexion Pharma

Amgen

BioMarin Pharmaceutical

Regeneron Pharmaceuticals

United Therapeutics

Vertex Pharmaceuticals

Earnings season is upon us and investors are pining for information about which stocks and sectors will do well.

7 Large Biotechs Expected to Outperform This Earnings Season

BRIDGEWATER, N.J., Sept. 9, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following virtual investor.

News for Insmed Stock (INSM)